New proteomic approaches for biomarker discovery in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 7, 2010, Pages 1239-1246

  Roda, Giulia ^a   Caponi, Alessandra ^a   Benevento, Marco ^b   Nanni, Paolo ^b   Mezzanotte, Laura ^b   Belluzzi, Andrea ^a   Mayer, Lloyd ^c   Roda, Aldo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

Crohn's disease; Protein profiling; Proteomics; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER;

CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENDOSCOPY; ENTERITIS; GENETIC SCREENING; GOLD STANDARD; HUMAN; PATIENT CODING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RELAPSE; REVIEW; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; PROTEOMICS;

EID: 77953705665     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21212     Document Type: Review

References (81)

1. Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol. 2004;20:318-327.
2. Price A. Overlap in the spectrum of non-specific inflammatory bowel disease-"colitis indeterminate." J Clin Pathol. 1978;31:567-577.
3. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122:1242-1247. (Pubitemid 34465166)
4. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic or unnecessary toys? Gut. 2006;55:426-431.
5. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation on inflammatory bowel disorders from constipation and diarrhoea predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002;14: 409-412.
6. Koelewijn CL, Schwartz MP, Samsom M, et al. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol. 2008;14:85-89.
7. Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210.
8. Eggena M, Targan SR, Iwanczyk L, et al. Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J Immunol. 1996;156: 4005-4011. (Pubitemid 26137688)
9. Eggena M, Cohavy O, Parseghian MH, et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun. 2000;14:83-97.
10. Vecchi M, Sinico A, Bianchi MB, et al. Recognition of bactericidial/ permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand J Gastroenterol. 1998;33: 1284-1288.
11. Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13:2028-2036.
12. Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001;96:758-765.
13. Mainardi E, Villanacci V, Bassotti G, et al. Diagnostic value of serological assays in pediatric inflammatory bowel disorders. Digestion. 2007;75:210-214.
14. Foley KF, Kao P. Biomarkers for inflammatory bowel disease. Clin Lab Sci. 2007;20:84-88.
15. Joossens S, Colombel JF, Vermeire S, et al. Panel of serologic antibodies in patients with indeterminate colitis. Gastroenterology. 2003; 124:A323.
16. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
17. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8-15.
18. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110:1810-1819.
19. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behaviour, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103: 665-681.
20. Kim BC, Park S, Han J, et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig Liver Dis. 2007;39:610-616.
21. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-1403.
22. Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis. 2003;9:302-307.
23. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996; 71:431-436.
24. Taylor KD, PLevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355. (Pubitemid 32322308)
25. Barahona-Garrido J, Camacho-Escobedo J, García-Martínez CI, et al. Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15: 1039-1043.
26. Angriman I, Scarpa M, D'Incà R, et al. Enzymes in feces: Useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68.
27. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum. 2008;51:1283-1291.
28. Xiang JY, Ouyang Q, Li GD, et al. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14:53-57.
29. Peterson CG, Sangfelt P, Wagner M, et al. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67:810-820.
30. Shitrit AB, Braverman D, Stankiewics H, et al. Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum. 2007;50: 2188-2193.
31. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;32:171-177.
32. Sipponem T, Savilahti E, Kärkkáinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti TNFa therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14:1392-1398.
33. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:414-422.
34. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
35. Bjarnason I, Sherwood R. Fecal calprotectin: a significant step in the non-invasive assessment of intestinal inflammation. J Pediatr Gastroenterol Nutr. 2001;33:11-13.
36. Baveye S, Elass E, Mazurier J, et al. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory response. Clin Chem Lab Med. 1999;37:281-286.
37. Sugi KSO, Hiarata I, Katsu K. Faecal lactoferrin as a marker of disease activity in inflammatory bowel disease: comparison with other neutrophil derived proteins. Am J Gastroenterol. 1996;91:927-934. (Pubitemid 26143531)
38. Kane SV, Sanborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-1314.
39. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
40. Dai J, Liu WZ, Zhao YP, et al. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007;42: 1440-1444.
41. Buderus S, Boone J, Lyerly D, et al. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036-1039.
42. Konokoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524-534.
43. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
44. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008;14:5115-5124.
45. Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel disease: current status and future directions with available technologies. Inflamm Bowel Dis. 2008;4:616-629.
46. Andoh A, Yoshida T, Yagi Y, et al. Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol. 2006;41:47-54.
47. Chamouard P, Desprez D, Hugel B, et al. Circulating cell-derived microparticles in Crohn's disease. Dig Dis Sci. 2005;50:574-580.
48. Kumari A, Pasini P, Daunert S. Detection of bacterial quorum sensing N-acyl homoserine lactones in clinical samples. Anal Bioanal Chem. 2008;391:1619-1627.
49. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433.
50. Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem. 2008;41:960-967.
51. Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom. 2007;21:4142-4148.
52. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198-207.
53. Wittmann-Liebold B, Graack HR, Pohl T. Two dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics. 2006;6:4688-703.
54. Bantscheff M, Schirle M, Sweetman G, et al. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem. 2007; 389:1017-1031.
55. Iliuk A, Galan J, Tao WA. Playing tag with quantitative proteomics. Anal Bioanal Chem. 2009;393:503-513.
56. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17:994-999.
57. Ross PL, Huang YL, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3:1154-1169.
58. Barcelo-Batllori S, André M, Servis C, et al. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics. 2002;2:551-560.
59. Felley-Bosco E, André M. Proteomics and chronic inflammatory bowel diseases. Pathol Res Pract. 2004;200:129-133.
60. Hardwdige P, Rodriguez-Escudero I, Goode D, et al. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli. J Biol Chem. 2004;279:20127-20136.
61. Shkoda A, Werner T, Daniel H, et al. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res. 2007;6:1114-1125.
62. Fogt F, Jian BO, Krieg RC, et all. Proteomic analysis of mucosal preparations from patients with ulcerative colitis. Mol Med Reports. 2008;1:51-54.
63. Hsieh SY, Shih TC, Yeh CY, et al. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics. 2006;6: 5322-5331.
64. Berndt U, Bartsch S, Philipsen L, et al. Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol. 2007;179: 295-304. (Pubitemid 46986545)
65. Liu BG, Cao YB, Cao YY, et al. Altered protein profile of lymphocytes in an antigen-specific model of colitis: a comparative proteomic study. Inflamm Res. 2007;56:377-384.
66. Huber LA, Pfaller K, Vietor I. Organelle proteomics: implications for subcellular fractionation in proteomics. Circ Res. 2003;92:962-968.
67. Groen AJ, de Vries SC, Lilley KS. A proteomics approach to membrane trafficking. Plant Physiol. 2008;147:1584-1589.
68. O'Morain C, Smethurst P, Levi J, et al. Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease. Scand J Gastroenterol. 1985;20:209-214. (Pubitemid 15131369)
69. Nanni P, Mezzanotte L, Roda G, et al. Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry. J Proteomics. 2009;72:865-873.
70. Andoh A, Tsujikawa T, Hata K, et al. Elevated circulating plateletderived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol. 2005;100:2042-2048.
71. Srirajaskanthan R, Winter M, Muller AF. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2005;17: 697-700.
72. Choi SK, Kasturi L, Tavakoly A, et al. Ulcerative colitis diagnosed in a patient with venous thromboembolism. Hospital Physician. 2008; 32-36.
73. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005;3:617-628.
74. Pap E, Pállinger E, Pásztói M, et al. Highlights of a new type of intracellular communication: microvesicle-based information transfer. Inflamm Res. 2009;58:1-8.
75. Huber V, Fais S, Iero M, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology. 2005;128:1796-1804.
76. Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost. 2005;94:488-492.
77. Böing AN, Hau CM, Sturk A, et al. Platelet microparticles contain active caspase 3. Platelets. 2008;19:96-103.
78. Nanni P, Levander F, Roda G, et al. A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3127-3136.
79. Murdoch TB, Fu H, Farlane SM, et al. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem. 2008;80:5524-5531.
80. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546-551.
81. Kumari A, Pasini P, Daunert S. Detection of bacterial quorum sensing N-acyl homoserine lactones in clinical samples. Anal Bioanal Chem. 2008;391:1619-1627.